Stryker (NYSE:SYK) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Stryker (NYSE:SYK) from a buy rating to a hold rating in a research note published on Saturday.

Other research analysts have also issued reports about the stock. BTIG Research reduced their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, William Blair restated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Stock Up 0.4%

Stryker stock opened at $306.74 on Friday. Stryker has a 1-year low of $281.00 and a 1-year high of $404.87. The firm has a market capitalization of $117.59 billion, a price-to-earnings ratio of 35.50, a P/E/G ratio of 1.93 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a 50 day simple moving average of $329.68 and a 200 day simple moving average of $351.73.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the firm posted $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts predict that Stryker will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Czech National Bank lifted its stake in Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Davis R M Inc. lifted its stake in Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC bought a new stake in Stryker in the third quarter worth $1,216,000. Kepler Cheuvreux Suisse SA bought a new stake in Stryker in the third quarter worth $27,952,000. Finally, Daymark Wealth Partners LLC lifted its stake in Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after purchasing an additional 37,307 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.